BioGenerator’s largest investment in any single company is paying off for St. Louis. Confluence Life Sciences, Inc. has been acquired by Aclaris Therapeutics, Inc. for the St. Louis company’s world-class research team, intellectual property and drug discovery assets.
Confluence will receive $20 million upfront, equally split between cash and stock and subject to customary adjustments. Confluence shareholders also are eligible to receive up to $80 million in contingent payments upon the achievement of certain development, regulatory and commercial milestones, as well as potential royalty payments on drug product sales.
Image: https://stlpartnership.com
